Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Cancer Res. 2014 Nov 28;75(5):880–891. doi: 10.1158/0008-5472.CAN-14-0573

Figure 5. The MAPK pathway is upregulated downstream of FGFRs in resistant GIST cells in response to imatinib.

Figure 5

A, GIST T1 and GIST 10R cells were treated with imatinib for 2 hours and cell lysates were subjected to immunoblot analysis using antibodies specific for total or phospho-AKT, C-RAF, MEK1/2, ERK1/2, or β-actin. B, GIST 10R cells were treated with the PI3K inhibitor PI103, C, the multi-kinase inhibitor CHIR-258 for 2 hours and cell lysates were subjected to immunoblot analysis, or D, a combination of imatinib and PD173074.